Growth Metrics

Integra Lifesciences Holdings (IART) Change in Accured Expenses (2016 - 2026)

Integra Lifesciences Holdings' Change in Accured Expenses history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 529.48% to $23.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.7 million, a 1099.4% increase, with the full-year FY2025 number at $26.7 million, up 1099.4% from a year prior.
  • Change in Accured Expenses hit $23.0 million in Q4 2025 for Integra Lifesciences Holdings, up from $5.8 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for IART hit a ceiling of $23.0 million in Q4 2025 and a floor of -$19.2 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged $2.7 million across 5 years, with a median of $3.8 million in 2023.
  • Biggest five-year swings in Change in Accured Expenses: surged 1944.11% in 2022 and later crashed 380.33% in 2024.
  • Tracing IART's Change in Accured Expenses over 5 years: stood at -$984000.0 in 2021, then surged by 1944.11% to $18.1 million in 2022, then crashed by 89.46% to $1.9 million in 2023, then plummeted by 380.33% to -$5.4 million in 2024, then soared by 529.48% to $23.0 million in 2025.
  • Business Quant data shows Change in Accured Expenses for IART at $23.0 million in Q4 2025, $5.8 million in Q3 2025, and $15.9 million in Q2 2025.